Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04952402 · ClinicalTrials.gov registry record · Phase 4
SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine
A Phase 4 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
NCT04952402 is a Phase 4 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 43 participants.
The verdict
NCT04952402, a Phase 4 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of mRNA COVID-19 vaccines in: • People with prior COVID-19 (SARS-CoV-2 infection) who were in the ACTIV-2/A5401 study. And • People who have never had COVID-19 (SARS-CoV-2 infection).
Interventions
- BIOLOGICAL Study-provided Moderna mRNA-1273 COVID-19 vaccine
- BIOLOGICAL Community-provided Moderna mRNA-1273 COVID-19 Vaccine
- BIOLOGICAL Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2021-07-09 |
| Est. Completion | 2023-01-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04952402
The ClinicalTrials.gov registry entry for NCT04952402 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Study-provided Moderna mRNA-1273 COVID-19 vaccine is the first listed.
NCT04952402 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04952402 about?
NCT04952402 is a clinical study titled "SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine". The purpose of this study is to evaluate the safety and efficacy of mRNA COVID-19 vaccines in: • People with prior COVID-19 (SARS-CoV-2 infection) who were in the ACTIV-2/A5401 study. And • People who have never had COVID-19 (SARS-CoV-2 infection).
What is the current status of trial NCT04952402?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2021-07-09. Estimated completion is 2023-01-10.
What interventions are being tested in trial NCT04952402?
The interventions under investigation include: Study-provided Moderna mRNA-1273 COVID-19 vaccine (BIOLOGICAL), Community-provided Moderna mRNA-1273 COVID-19 Vaccine (BIOLOGICAL), Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04952402?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.